Abstract Number: 2527 • 2018 ACR/ARHP Annual Meeting
Long-Term Safety with Sarilumab Plus Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) and Sarilumab Monotherapy in Rheumatoid Arthritis (RA): An Integrated Analysis with 9,000 Patient-Years (Pt-Yrs) of Follow-up
Background/Purpose: Sarilumab has shown efficacy in RA both as monotherapy and in combination with csDMARDs in Phase 3 trials. We assessed long-term safety from the…Abstract Number: 20 • 2017 ACR/ARHP Annual Meeting
Low Molecular Weight BAFF Receptor Antagonists Restrain Infiltration of B Cells into Organs of Autoimmune Model Mice By Suppressing B Cell Activation
Background/Purpose: We have reported that soluble BAFF (sBAFF) robustly increased IL-6 production by peripheral monocytes of patients with primary Sjögren’s syndrome (pSS) and that the…Abstract Number: 21 • 2017 ACR/ARHP Annual Meeting
Reciprocal Regulation of B Cells on Bleomycin-Induced Scleroderma Model: IL-6-Producing Effector B Cells Play a Pathogenic Role, While IL-10-Producing Regulatory B Cells Play a Protective Role
Background/Purpose: IL-10-producing regulatory B (Breg) cells negatively regulate autoimmune diseases. We reported that Breg cells play a protective role in a mouse model of systemic…Abstract Number: 548 • 2017 ACR/ARHP Annual Meeting
LDL and HDL Changes with Sirukumab Treatment Are Anti-Atherogenic: Results from Two Phase 3 Trials in Patients with Rheumatoid Arthritis
Background/Purpose: Sirukumab (SIR), a human monoclonal antibody that selectively binds to the IL-6 cytokine with high affinity, has demonstrated efficacy in RA in the phase…Abstract Number: 549 • 2017 ACR/ARHP Annual Meeting
Increases in Lipid Levels Following Sirukumab Treatment Are Associated with Suppression of Inflammation in Rheumatoid Arthritis: Results from Two Phase 3 Trials
Background/Purpose: Understanding interactions of inflammatory cytokines and lipid metabolism in RA is of considerable interest. Blocking IL-6 receptor elevates lipid levels in RA while lowering…Abstract Number: 782 • 2017 ACR/ARHP Annual Meeting
Serum IL-6, SAA and Calprotectin As Biomarkers in Giant Cell Arteritis and Polymyalgia Rheumatica
Background/Purpose: GCA and PMR are closely related inflammatory diseases. The diagnostic criteria of both disorders depend on a combination of clinical features and elevated ESR…Abstract Number: 788 • 2017 ACR/ARHP Annual Meeting
Mast Cell Mediated Inhibition of Systemic IL-6 in candida Albicans Water-Soluble Fraction (CAWS) Induced Model of Large Vessel Vasculitis
Background/Purpose: In forms of large vessel vasculitis (LVV) systemic IL-6 has been shown to follow disease activity. Furthermore, IL-6 inhibition is an effective treatment for…Abstract Number: 891 • 2017 ACR/ARHP Annual Meeting
Long-Term Efficacy and Safety of Tocilizumab in Patients with Refractory Takayasu Arteritis Treated Continuously over 52 Weeks: Results from Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial and Open-Label Extension in Japan
Background/Purpose: Tocilizumab (TCZ), a humanized anti–IL-6 receptor antibody, showed a favorable trend toward relapse suppression in patients (pts) with refractory Takayasu arteritis (TAK) in a…Abstract Number: 955 • 2017 ACR/ARHP Annual Meeting
In Vitro Effects of CR6086, a Potent ProstaglandinE2 Subtype 4 Receptor Antagonist, on Bone Erosive Pathways
Background/Purpose: CR6086 is a selective EP4 receptor antagonist immunomodulator in clinical development for rheumatoid arthritis (RA). In animal models of RA, it demonstrated a superior…Abstract Number: 973 • 2017 ACR/ARHP Annual Meeting
IL-6 and TNF-a Cooperate to Modulate the Cell Cycle of RA-Fibroblast-like Synoviocytes Via Cyclin Dependent Kinase Inhibitors
Background/Purpose: IL-6 and TNF-α play an important role in the pathogenesis of RA, and the proliferation of RA-synoviocytes (FLS) is controlled by cell cycle regulators…Abstract Number: 1467 • 2017 ACR/ARHP Annual Meeting
Changes in the Immune Response of RA Patients Induced By 1 Year of Tocilizumab
Background/Purpose: Tocilizumab, a humanized anti-human IL-6 receptor antibody that blocks the signaling of IL-6/IL-6R complex, is an effective treatment in chronic inflammatory rheumatoid arthritis (RA).…Abstract Number: 1478 • 2017 ACR/ARHP Annual Meeting
Inadequate Clinical Response to Sirukumab, an Anti-IL-6 Monoclonal Antibody, Can be Predicted after a Single Dose of Treatment in Patients with Rheumatoid Arthritis
Background/Purpose: Response to therapy in rheumatoid arthritis (RA) is heterogeneous. Early identification of patients (pts) who are unlikely to achieve a meaningful clinical response may…Abstract Number: 1908 • 2017 ACR/ARHP Annual Meeting
Long-Term Efficacy and Safety Results of a Global Phase 3 Trial of Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis Despite Disease-Modifying Anti-Rheumatic Drug Treatment
Background/Purpose: In patients (pts) with active rheumatoid arthritis (RA) despite DMARD treatment, sirukumab, a human monoclonal antibody that selectively binds to the IL-6 cytokine with…Abstract Number: 2437 • 2017 ACR/ARHP Annual Meeting
Long-Term Effect of Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, on Radiographic Progression in Patients with Active Rheumatoid Arthritis Despite Disease-Modifying Anti-Rheumatic Drug Treatment: Results of a Global Phase 3 Trial
Background/Purpose: In the SIRROUND-D study, sirukumab (SIR), a human monoclonal antibody that selectively binds to the IL-6 cytokine with high affinity, significantly reduced radiographic progression…Abstract Number: 2472 • 2017 ACR/ARHP Annual Meeting
Integrated Phase 3 Safety Results of Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis
Background/Purpose: Sirukumab (SIR), a human monoclonal antibody that selectively binds to the IL-6 cytokine with high affinity, is in development for rheumatoid arthritis (RA) in…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 9
- Next Page »